Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1982 Oct 16;285(6348):1069-71.
doi: 10.1136/bmj.285.6348.1069.

Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin

E Stranden, O K Roald, K Krohg
Clinical Trial

Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin

E Stranden et al. Br Med J (Clin Res Ed). .

Abstract

The selective 5-hydroxytryptamine2-(5-HT2)-receptor-blocking agent ketanserin was given in a dose of 10 mg intravenously to nine patients with Raynaud's phenomenon. The effect on blood flow was assessed by photopletysmography and measurments of skin temperature. Digital blood flow and skin temperature increased significantly after ketanserin injection, whereas the placebo (saline 9 g/l) had no such effect. This study suggests that ketanserin may be useful in the treatment of Raynaud's phenomenon.

PubMed Disclaimer

References

    1. Prog Cardiovasc Dis. 1975 Sep-Oct;18(2):123-46 - PubMed
    1. Arch Intern Med. 1979 Jan;139(1):89-92 - PubMed
    1. Semin Arthritis Rheum. 1981 May;10(4):282-308 - PubMed
    1. Br Med J (Clin Res Ed). 1982 Feb 20;284(6315):537-9 - PubMed
    1. Eur J Pharmacol. 1982 Feb 5;77(4):281-7 - PubMed

Publication types

LinkOut - more resources